Skip to main content
Premium Trial:

Request an Annual Quote

4basebio Announces Treasury Share Buyback

NEW YORK — 4basebio, formerly Expedeon, said on Tuesday that it will buy back 2 million of its treasury shares, representing approximately 4 percent of the company's current share capital.

4basebio said that it will price the treasury shares between €1.60 to €1.85 ($1.77 to $2.05) apiece, with the final purchase price to be determined after the expiry of the offer's acceptance period. The Heidelberg, Germany-based firm said that it is considering retaining the shares in treasury, potentially in order to help fund a future company or equity acquisition.

"Our objective remains a balanced use of the company's high level of liquid funds, some of which is intended to the benefit of our shareholders," 4basebio CFO David Roth said in a statement. "The buyback program is intended to offer an attractive opportunity for our investors to realize value should they so wish."

4basebio changed its name from Expedeon earlier this month following the €120 million sale of its immunology and proteomics businesses to Abcam. 4basebio now focuses on the manufacture and sale of DNA and DNA products for research and therapeutic applications.

Prior to the sale, Expedeon reported having €3.3 million in cash and cash equivalents.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.